Sonoma Pharmaceuticals (SNOA) Capital Expenditures (2010 - 2026)

Sonoma Pharmaceuticals' Capital Expenditures history runs 17 years deep, the most recent figure standing at $29000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures fell 38.3% year-over-year to $29000.0 in Q1 2026; TTM through Mar 2026 was $192000.0, a 140.0% increase from a year earlier, with the FY2026 full-year figure at $192000.0, up 140.0% from the prior year.
• Capital Expenditures retreated to $29000.0 in Q1 2026 per SNOA's latest filing, from $47000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $190000.0 in Q1 2023 and bottomed at -$18000.0 in Q1 2024.
• The 5-year median for Capital Expenditures is $25000.0 (2022), against an average of $35588.2.
• Across the five-year window, Capital Expenditures jumped 3000.0% in 2022 and tumbled 109.47% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $31000.0 in 2022, then tumbled by 96.77% to $1000.0 in 2023, then soared by 100.0% to $2000.0 in 2024, then soared by 2250.0% to $47000.0 in 2025, then sank by 38.3% to $29000.0 in 2026.
• Per Business Quant, the three latest SNOA Capital Expenditures figures stand at $29000.0 (Q1 2026), $47000.0 (Q4 2025), and $10000.0 (Q3 2025).